Stroke Research

Stroke is classified as both a neurological and a cardiovascular disease, as it is a disruption in blood supply to the brain which causes the neurological abnormalities. There are two types of stroke; ischemic and hemorrhagic.

Stroke Research Products Targets

Products for Stroke Research

Cat.No. Product Name Information/Activity
BCC1234 Calpain Inhibitor II, ALLM Cathepsin inhibitor,Odanacatib (MK 0822) is a potent, selective, and neutral inhibitor of cathepsin K (human/rabbit) with IC50 of 0.2 nM/1 nM, and demonstrated high selectivity versus off-target cathepsin B, L, S. Phase 3.
BCC1141 CA 074 CA-074 is a potent inhibitor of cathepsin B with a Ki of 2 to 5 nM.
BCC2350 Acetyl-Calpastatin (184-210) (human) Selective calpain inhibitor
BCC2351 Calpeptin Calpeptin is a potent, cell penetrating calpain inhibitor, with an ID50 of 40 nM for Calpain I in human platelets. Calpeptin is also an inhibitor of cathepsin K.
BCC1222 E-64 E-64 (Proteinase inhibitor E 64) is a potent irreversible inhibitor against general cysteine proteases with IC50 of 9 nM for papain.
BCC1127 E 64d Aloxistatin (E64d) is a cell-permeable and irreversible broad-spectrum cysteine protease inhibitor.
BCC2361 L 006235 Potent cathepsin K inhibitor
BCC2352 MDL 28170 MDL-28170 (Calpain Inhibitor III) is a potent, selective and membrane-permeable cysteine protease inhibitor of calpain that rapidly penetrates the blood-brain barrier following systemic administration. MDL-28170 also block γ-secretase.
BCC1233 Calpain Inhibitor I, ALLN MG-101 is a potent inhibitor of cysteine proteases which inhibits calpain I, calpain II, cathepsin B and cathepsin L with Kis of 190, 220, 150 and 500 pM, respectively.
BCC1227 MG-132 MG-132 (Z-Leu-leu-leu-al) is a potent proteasome and calpain inhibitor with IC50s of 100 nM and 1.2 μM, respectively. MG-132 effectively blocks the proteolytic activity of the 26S proteasome complex. MG-132, a peptide aldehyde, also is an autophagy activator. MG-132 also induces apoptosis.